Abstract: Primary tumours of thymus, thymoma and thymic carcinoma, are very rare, they represent less than 1 % of all neoplasms. The most common manifestation of thymoma with appearance of 40 to 50 % of the neuromuscular autoimmune disease is myasthenia gravis (MG). The performance of a complete resection is the most predictive indicator for long-term survival of patients with thymic tumour, also important prognostic factors are the histological type of thymic tumour and its invasiveness. The aim of our study is to study the long-term survival of patients after the resection of the tumour, as well as enhanced effi ciency of radical thymectomy in the complex treatment of myasthenia gravis. From 1989 to 2010 we operated on 369 patients with MG. Out of 49 patients (13.7 %) 38 cases (76.6 %) were thymomas and 11 cases (23.4 %) thymic carcinomas. Complete removal of tumours (stage I, II, and III) were performed in 45 (92 %) cases. Of the 41 living patients (83.7 %), three (7.3 %) were diagnosed with metastatic thymic carcinoma or thymoma, and treated with adjuvant therapy. In one case, the patient died due to generalization of the thymic carcinoma. Statistical analysis with KaplanMeier method showed better overall survival of patients with thymoma than patients with thymic carcinoma. The difference in survival curves was not signifi cant. (Mantel-Cox p = 0.479, Generalized Wilcoxon p = 0.326). In terms of treatment of Myasthenia gravis associated with thymoma, we achieved 70 % successful clinical and pharmacological remission. On the other hand, paraneoplastic MGAT has the worst prognosis of all the other forms of MG. The difference between MGAT to every other form of MG was statistically signifi cant (Tab. 6, Fig. 1 Thymomas with thymic carcinomas present primary tumours of thymus having indolent course and sporadic occurrence. Generally, they account for less than 1 % of all oncological neoplasms but comprise 20-25 % of all mediastinal tumours (1). A larger body of literature now provides further insight into biological behaviour of thymoma playing a role in the pathogenesis of myasthenia gravis (MG). Therefore, myasthenia gravis associated with thymomas (MGAT), is also called paraneoplastic, which is an organspecifi c autoimmune disorder characterised by wavering muscular weakness and abnormal fatigue. In imunopathogenesis of MGAT participate thymic and extrathymic mechanisms. Henceforth, radical surgical removal of thymoma does not always lead to clinical improvement of MG and decreasing titre of autoantibodies that block acetylcholine receptors (AChR) (2).
Thymomas with thymic carcinomas present primary tumours of thymus having indolent course and sporadic occurrence. Generally, they account for less than 1 % of all oncological neoplasms but comprise 20-25 % of all mediastinal tumours (1) . A larger body of literature now provides further insight into biological behaviour of thymoma playing a role in the pathogenesis of myasthenia gravis (MG). Therefore, myasthenia gravis associated with thymomas (MGAT), is also called paraneoplastic, which is an organspecifi c autoimmune disorder characterised by wavering muscular weakness and abnormal fatigue. In imunopathogenesis of MGAT participate thymic and extrathymic mechanisms. Henceforth, radical surgical removal of thymoma does not always lead to clinical improvement of MG and decreasing titre of autoantibodies that block acetylcholine receptors (AChR) (2) .
Thymomas are characterised by their variability of morphological appearance and are often associated with various autoimmune diseases. Previous studies report the correlation between their morphological appearance and clinical behaviour. Based on the facts, the last histological classifi cation was presented by the WHO in 1999 which was slightly modifi ed in 2004 showing a relation to clinical behaviour, tumour staging system, the prognosis and the association with MG (3, 6, 7) (Tab. 1).
According to the WHO classifi cation, epithelial tumours are divided in two main groups. Thymomas are characterised as organotypic thymus-like tumours classifi ed in 5 types (A,AB, B1, B2 and B3), taking into account the morphology of epithelial cells as well as the ratio of epithelial cells to lymphocytes (4, 5, 6, 7) . Thymic carcinomas are described as epithelial malignancies, their appearance resembles tumours originating from the other organs and they have no capsule and infi ltrate surrounding structures. The most common subtypes of thymic carcinomas are: squamocellular, basaloid, mucoepidermoid, lymphoepithelioma-like, clear-cell, undifferentiated/anaplastic and group neuroendocrine tumours (8, 9) .
Besides determination of histological type of thymoma, the staging system has prognostic value as well. A TNM staging system that has gained widespread acceptance was proposed by Masaoka and his colleagues in 1981 (Tab. 2). It is based on the extent of either macroscopic or microscopic invasion into mediastinal structures. Peri-operative determination of tumour extent followed by radical or palliative surgical removal is considered as main prognostic factor (10) .
The sex distribution of patients with thymic tumours is roughly equal in the broad age, with a peak around 40 to 60 years of age (11, 12) . Thymomas are associated with several parathymic syndromes which is an autoimmune condition, most commonly with MG occurring in 40 to 50 % of patients (13, 14) . Conversely, approximately 10 to 15 % of patients with MG are found to have thymoma (15, 16, 17) . Paraneoplastic MG is a seropositive form with antibodies against AChR leading to the diagnosis of thymoma, which is asymptomatic because of slow growth and even to a farther reaching extent. Occasionally, it may be accidentally found as mediastinal mass by computer tomography. Those with local symptoms related to the intrathoracic mass may have chest pain, cough, afterwards dyspnoea, haemoptysis, stridor and dysphonia. Superior vena cava syndrome, Horner´s syndrome, arrhythmias and weight loss occur rarely with more aggressive tumours. By the infi ltration of oesophagus they may cause dysphagia with odynophagia. Thymic tumours rarely metastasize affecting intrathoracic structures as pericardium, pleura and diaphragm or the distant sites (18, 18, 20) .
Surgical treatment is the mainstay of treatment of thymomas, because the vast majority (90-95 %) of these tumours are localized. Radical operation with removing the adjacent fatty tissue has shown to be the most signifi cant prognostic factor for the overall survival (21, 22) . The 10-year overall survival rate after complete resection is 88 %, 70 %, 57 % and 38 % for I, II, III, and IV stage respectively (23) . The best measure of outcome after resection may be the recurrence rate that occurs most likely after the resection of extensive tumours, because it is largely dependent on its invasion. An average of 80 % of all recurrences are local and they should be completely resected whenever it is possible and adjuvant therapy should be administered. This approach is associated with good long-term survival (13, 24, 25) .
Patients and methods
A retrospective review of all patients undergoing resection for thymic tumours associated with MG was performed at a single centre between January 1989 and December 2010. During this time period, 369 patients underwent surgery as the treatment of MG.
Of the total operated patients 49 were selected with post-operative fi ndings of thymic tumours.
All patients were diagnosed with MG by the neurologist in Myasthenia centre for Neuromuscular disorders at Bratislava University Hospital. The diagnosis was established based on neurological a myological investigation, set of titre of antibodies (antibodies against AChR and muscular-specifi c tyrosine-kinase, antistriatal antibodies) and using electrophysiological investigation EMG (repetitive stimulation, single fi bre electromyography). Each patient underwent radiology to confi rm or alternatively exclude the presence of thymic tumour. Initially, X-ray imaging was used having very low sensitivity, only visualising gross masses of tumours. Performance of computed tomography has markedly given more precise details of thymic tumours, their relation to great vessels and surrounding structures. A vast majority of patients with MGAT was administered immunosuppresive therapy preoperatively, in combination with plasmapheresis and intravenous imunoglobine in some cases. After achieving a decrease of clinical symptomatology of MG whenever most of the patients were asymptomatic having mantained low-doses of imunosupressive therapy, then the operation was indicated. The preoperative therapy is necessary due to tolerance of general anesthesia, the course of operation and avoidance of deterioration of MG.
We preferred performing thymectomy, an upper partial sternotomy, for the advantage of good exposure. Through a 10 to 12 cm skin incision, with the sternum retracted, adequate visualization of thymus and its cervical extensions is obtained for performance of total radical thymectomy that means removing of whole thymus and adjacent fatty tissue from anterior mediastinum. Once the thymus is dissected completely, the pericardium, ascendent aorta, anonyma vein and both pleura are visualized. By the macroscopic fi ndings of thymic tumours the effort was highly made to undertake more extensive operation and complete resection. The sternum is then sutured using three metal wires and having a chest tube placed retrosternally for adequate postoperative drainage of mediastinum.
Upon completion of the operation, all patients were followed up by a neurologist in myasthenic centre for neuromuscular disorders. In case of histological fi ndings of thymic tumour the assessment of administration of adjuvant therapy was made by an oncologist. Histological fi ndings were initially classifi ed according to former morphological system proposed by Bernatz then to the Muller-Hermelink system and in recent years WHO system. Due to un-unifi ed classifi cation system in the past 20 years, we were not able to distribute patients according to the newest classifi cation system. Therefore, we selected the patients into two groups in accordance with histological type, thymoma or thymic carcinoma. Based on the results of surgical treatment we evaluated the effi ciency of radical thymectomy and survival period in 
Results
Radical thymectomy for MG was performed in 369 patients and 49 of them (13.3 %) had histology of thymic tumours. Thymic tumours distribution of patients were 38 (76.6 %) thymomas and 11 (23.4 %) thymic carcinomas. The baseline characteristics of patients are shown in Table 3 .
The complete resection of tumours (stage I, II, and III) was achieved in 45 (92 %) cases and only in 4 (8 %) patients with stage III and IVa a subtotal resection (debulking) was performed because of advance state of thymic carcinoma and infi ltration of great vessels and pericardium. However, thymic tumours in stage III were completely resected in 57.1 %. The occurrence of thymic tumours in accordance with their stage of invasion proposed by Masaoka system are shown in Table 4 . Thymic tumours of stage I and II occurred in 41 (83.7 %) patients that is a considerable result in terms of overall survival. The rest of the patients (16.7 %) diagnosed with stage III and IVa received adjuvant radiotherapy.
In one case we decided to re-operate. It was a local recurrence of thymic tumour diagnosed 10 years after complete resection of thymic carcinoma classifi ed in stage III. The diagnosis was made by performance of PET-CT and local metastases of both lungs were also found. We decided on the removal of the local recurrence but only biopsy could be performed resulting in confi rmation for local recurrence of thymic carcinoma. Then the patient received chemotherapy.
With a mean time of 9.9 years, (min.2.3 -max 20.2 years), a follow up of 41 patients (83.7 %) resulted in disease-free survival. Two of the patients are unknown and fi ve died with no relation to the underlying disease. The cause of death for three patients were heart failure prior to heart attack, one progression of lung fi brosis of chronic obstructive lung disease and one prior to trauma accident. Only one case of death was due to generalised disseminated thymic carcinoma, in spite of the use of all three common therapeutic modalities which included surgery, radiation and chemotherapy. In long term follow-up of patients, three of them were diagnosed with intrathoracic metastases of confi rmed thymic carcinoma and thymoma B3. After this diagnosis they received chemotherapy with an objective average response. The overall survival of observing groups with mean time of 10 years with follow-up is remarkably well. Statistical analysis with Kaplan-Meier method (Fig. 1) shows better overall survival of patients with thymoma than patients with thymic carcinoma. The difference in survival curves was not signifi cant. (Mantel-Cox p=0.479, Generalized Wilcoxon p=0.326).
Concerning the treatment of MG in the observed 47 patients, the clinical remission in 16 patients (34 %) and pharmacological remission in 17 patients (36 %) were achieved. The achievement of successfuly treated patients were 70 % of all. Patients in clinical and pharmacological remission were mostly with thymoma in 68.8 % and 88.8 % respectively than with thymic carcinoma in 31.2 % and 11.8 % respectively (Tab. 5). The mild improvement of MG symptomatology has been found in patients with thymic carcinoma. Statistical evaluation showed signifi cant difference between the mentioned groups (Chi-Square test p=0.034). On the other hand, the paraneoplastic MG has the worst prognosis in comparison to other different forms of MG. The outcome of treated patients with different forms of MG is shown in Table 6 . The highest percentage of achievement in the clinical remission was seen with seropositive MG without thymic tumour, but the lowest percentage in patients having MGAT with a statistical difference (Chi-Square test p=0.015).
Discussion
The complex treatment of thymic tumour associated with paraneoplastic MG has positive progression. In the era before immunosuppressive therapy thymectomy reached 50 % mortality rate in the early postoperative period, usually because of respiratory failure. The substantial cause of the unfavourable outcome was a conservative attitude for surgery as well. The indication for surgery was set in the late stage of MG (26, 20) . The main change in the pathogenetic therapy and early indication for surgery connected with the immunosuppressive preoperative therapy caused thymectomy as operative intervention with minimal mortality (2.5 %) and morbidity (4.5 %). In our 20-years experience of performing radical transsternal thymectomy there was one case with postoperative death. Thymectomy was performed as the last option after exhausting all conservative treatment for a patient in myasthenic crisis to ameliorate health condition. Any other consequential complication was not remarked with postoperative morbidity 9.5 %.
In terms of surgery and oncology, thymic tumours became the absolute indication for operative treatment. The higher age of a patient or serious co-morbidity might be contraindication for surgery. The Medial sternal split is the most common approach to the anterior mediastinum. The size of performed sternotomy, partial or total, is based on the surgeon's decision and local fi ndings.
Long discussed prognostic factor is the histological type of thymoma. Currently, there are claims of the correlation between different types of tumours and their invasiveness. Patients with thymoma type A, AB, B1 have a signifi cantly longer survival rate than patients with a thymoma type B2 or B3. Several proofs show the worse prognosis for patients with thymic tumours (6, 7). In our series there is still a small number of patients classifi ed according to the latest WHO classifi cation. Until now it is recorded that the patient's death was just the generalization of the thymic carcinoma. Three other patients with intrathoracic metastases have verifi ed thymic carcinoma and thymoma B3. This is in accordance with the results of several studies of a poor prognosis of the mentioned types of thymoma, as well as, the very fact of correlated classifi ed tumours by the WHO.
It is becoming clearer that the pathogenesis of MG patients with thymoma differs from other types of MG pathogenesis. The main functional difference is the presence of intratumorous production of autoantibodies. The mere initiation of autoimmune mechanism is in thymoma but the continuation of their activation of im- munocompetent cells which produce autoantibodies are possible in places of retained residual thymus outside of the tumour. There are also assumptions that the activation of autoantibodies may take place in the non-thymatous immune system such as; lymph nodes, spleen and bone marrow. That would explain why thymectomy does not always decrease the titre of autoantibodies, while in some cases it improves clinical symptomatology MG (18, 27, 28) . The effectiveness of thymectomy in the treatment of MGAT is still in question and the literature is uncertain. In accordance to our evaluation of the success of clinical and pharmacological remission the results were outstanding. Therefore, we consider thymectomy in the treatment of MGAT to be essential and effective.
Patients with early diagnosis of thymoma associated with MG, individually adjusted to preoperative immunosuppressive therapy followed by radical thymectomy, achieved remarkable results in long-term survival and contributed signifi cantly in the treatment of paraneoplastic MG.
